Healthcare
Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application
Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.
Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicines
The Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning why other vital medications lack similar oversight when sold at exorbitant rates. The Solicitor General emphasized the importance of maintaining a balance between drug availability and market dynamics in determining prices.
Joint pain isn’t the same for everyone. Should treatment be?
Joint pain is frequently dismissed as an inevitable consequence of aging; however, it may point to significant underlying issues. Symptoms like stiffness and inflammation warrant a consultation with healthcare professionals. Various forms of arthritis necessitate unique treatment approaches, and symptoms can differ from person to person. Maintaining an active lifestyle and a healthy weight is crucial for preserving joint health.
Tricog Health targets 100 million cardiac screenings by 2030: CEO Dr Charit Bhograj
Bengaluru-based Tricog Health aims to conduct 100 million cardiac screenings by 2030, having screened over 41 million patients since its founding in 2014. The healthtech firm uses AI-enabled ECG devices and specialist reviews to detect heart conditions, with operations across several Indian states and 14 countries. Its technology aims to reduce diagnosis delays and improve early detection of cardiovascular diseases.
National Formulary of India lists drugs not approved by CDSCO, DCGI seeks explanation from IPC
The National Formulary of India released its latest edition amidst concerns regarding unapproved drugs included in it. The Drug Controller General of India has communicated with the Indian Pharmacopoeia Commission regarding this discrepancy. Several drugs listed in NFI 2026 have not received approval from the Central Drugs Standard Control Organisation. Stakeholders have also raised complaints about the unavailability of the online version of NFI 2026.
Health ministry proposes curbs on prescription drug ads by retailers, wholesalers and distributors
The union health ministry has proposed extending advertising restrictions on prescription drugs to retailers and distributors. This change will bar them from advertising certain medicines without prior government approval. The amendment affects drugs covered under Schedules H, H1, and X, which require medical oversight. The existing regulations already apply to pharmaceutical manufacturers. The recommendation for this amendment comes from the Drugs Technical Advisory Board.
Pharmacies, drug distributors may need approval to advertise prescription medicines
The Union health ministry aims to restrict advertising of prescription drugs by retailers and distributors, requiring prior government approval. This measure is in response to concerns about unauthorized promotion and inappropriate self-medication. A new sub-rule is proposed to ensure compliance across the pharmaceutical supply chain. Stakeholders are invited to provide feedback on this draft notification within 30 days.
Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%
The government has announced a cap on trade margins for non-scheduled anti-cancer drugs at 30%. This move is expected to lower the prices of cancer medications by 20 to 70%. Officials anticipate substantial annual savings for patients reaching approximately ₹2,500 crore. The initiative aims to enhance affordability and accessibility while curbing excessive trade markups. Concerns have been raised regarding the effectiveness of such measures in making treatments affordable.
National Medical Commission bans doctors & hospitals from using AI-generated patient testimonials, fake cure claims in medical ads
The National Medical Commission has implemented new ethical advertising guidelines affecting doctors and hospitals. These guidelines prohibit the use of artificial intelligence for generating promotional content or testimonials. Measures have also been taken to restrict paid patient solicitation and misleading claims in advertisements. Strict penalties have been established for non-compliance, including warnings and license suspensions.
Govt set to cap trade margins on more cancer drugs before SC hearing
The Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda will make the announcement just ahead of a Supreme Court hearing on October 12. This decision comes after concerns regarding the price gap between retailer prices and MRP of some cancer medications. Trade margins were capped previously, leading to significant price reductions on several anti-cancer drugs.
RECENT NEWS
- Madhoo backs Rashmika Mandanna over South Indian accent criticism; says ‘own it, girl’
- Ayushmann Khurrana about an early rejection story involving Karan Johar
- Saiee M Manjrekar’s look from Ram Charan-backed ‘The India House’ leaks
- Kamal reveals how Mammootty’s joke led to ‘Mazhayethum Munpe’
- Student sets mehndi record in Karnataka
